Menveo

RSS

meningococcal group A, C, W-135 and Y conjugate vaccine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Menveo. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Menveo.

This EPAR was last updated on 13/04/2018

Authorisation details

Product details
Name
Menveo
Agency product number
EMEA/H/C/001095
Active substance
meningococcal group A, C, W-135 and Y conjugate vaccine
International non-proprietary name (INN) or common name
meningococcal group A, C, W-135 and Y conjugate vaccine
Therapeutic area (MeSH)
  • Immunization
  • Meningitis, Meningococcal
Anatomical therapeutic chemical (ATC) code
J07AH08
Publication details
Marketing-authorisation holder
GSK Vaccines S.r.l.
Revision
22
Date of issue of marketing authorisation valid throughout the European Union
14/03/2010
Contact address
via Fiorentina 1
53100 Siena
Italy

Product information

14/03/2018 Menveo - EMEA/H/C/001095 - N/0073

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

BACTERIAL VACCINES

Therapeutic indication

Prefilled syringe

Menveo is indicated for active immunisation of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

The use of this vaccine should be in accordance with official recommendations.

Vials

Menveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

The use of this vaccine should be in accordance with official recommendations.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating